3 completed, 2 not yet recruiting, 2 unknown, 1 active not recruiting. 7 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Not yet recruiting 2, Unknown 2, Completed 1, Recruiting 1, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Cervical Neoplasms: new trials by email Literature Review of Cervical Neoplasms trials Research Report on Cervical Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial Adebrelimab - Cervical Neoplasms | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 35 | 2026-08-01 | 2026-07-28 |
| An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy Zanidatamab - Neoplasms, Solid Tumors | Phase 2 | Not yet recruiting | Haihua Yuan | 10 | 2026-06-15 | 2026-06-08 |
| Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor Trastuzumab Rezetecan - Solid Tumors, Neoplasms (Cancer / Tumors) | Phase 2 | Not yet recruiting | Haihua Yuan | 15 | 2026-06-15 | 2026-06-08 |
| A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations ATV-1601, ATV-1601 + Fulvestrant - Advanced Solid Tumors, Breast Cancer | Phase 1 | Active not recruiting | Atavistik Bio, Inc | 134 | 2025-07-29 | 2026-08-07 |
| Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors Cadonilimab, Nab paclitaxel - Uterine Cervical Neoplasms, Cancer of Cervix | Phase 2 | Unknown | Women's Hospital School Of Medicine Zhejiang University | 58 | 2023-06-01 | 2023-05-06 |
| Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies GeneTherapy - Cervical Intraepithelial Neoplasia, Cervical Neoplasms | Enrolling by invitation | National Cancer Institute (NCI) | 1000 | 2020-05-08 | 2026-10-02 | |
| Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer Sintilimab, quadrivalent HPV vaccine - Uterine Cervical Neoplasms, Cervical Cancer | Phase 2 | Unknown | Buhai Wang | 20 | 2019-07-31 | 2019-09-20 |
| Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens BD HPV Assay on Viper LT, Colposcopy - Cervical Neoplasms, Human Papillomavirus | Completed | Becton, Dickinson and Company | 6730 | 2014-10-01 | 2021-02-08 | |
| Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial) Boost radiation - Cancer of the Cervix, Cervical Neoplasms | Not applicable | Completed | Duke University | 12 | 2012-06-04 | 2021-02-08 |
| Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients tri-weekly cisplatin - Cervical Neoplasms | Phase 2 | Withdrawn | Korea Cancer Center Hospital | 2009-01-01 | 2018-08-13 | |
| Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer CONCURRENT CHEMORADIATION (CISPLATIN) - CERVICAL NEOPLASMS | Phase 2 | Completed | Korea Cancer Center Hospital | 71 | 2006-03-01 | 2014-05-01 |
| A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer neoadjuvant chemotherapy + radical hysterectomy, radical hysterectomy - Cervical Neoplasms | Phase 3 | Terminated | Haruhiko Fukuda | 200 | 2002-02-01 | 2016-09-22 |
Uterine Cervical Neoplasms (12) · Endometrial Neoplasms (3) · Neoplasms (3) · Carcinoma, Transitional Cell (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Biliary Tract Neoplasms (1) · Breast Diseases (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Genital Neoplasms, Female (1) · Neoplasm Metastasis (1) · Neoplasms by Site (1)
Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Genital Diseases (12) · Genital Diseases, Female (12) · Urogenital Diseases (12) · Uterine Cervical Diseases (12) · Uterine Diseases (12) · Genital Neoplasms, Female (11) · Neoplasms by Site (11) · Urogenital Neoplasms (11) · Uterine Neoplasms (11) · Neoplasms (9) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Adnexal Diseases (2)
Cisplatin (1) · Colposcopy (1) · Fulvestrant (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · Neoadjuvant Therapy (1) · Taxes (1) · sintilimab (1) · zanidatamab (1)
Haihua Yuan (2) · Korea Cancer Center Hospital (2) · Atavistik Bio, Inc (1) · Becton, Dickinson and Company (1) · Buhai Wang (1) · Duke University (1) · Haruhiko Fukuda (1) · National Cancer Institute (NCI) (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Women's Hospital School Of Medicine Zhejiang University (1)
United States (4) · China (2) · South Korea (2) · Canada (1) · France (1) · Japan (1) · Singapore (1) · Spain (1)
Buhai Wang (1) · Ge Lou, PHD (1) · Junzo Chino, MD (1) · Sang-Young Ryu, MD (1) · Scott M Norberg, D.O. (1) · Tobi Karchmer, MD (1) · Toshiharu Kamura, MD, PhD (1) · Yuechao Wu (1)
PMID 29095678, PMID 29787422, PMID 29967015, PMID 30826965, PMID 39608975